[SCHEDULE 13G/A] Vigil Neuroscience, Inc. SEC Filing

Rhea-AI Filing Summary

Glazer Capital, LLC and Paul J. Glazer reported beneficial ownership of 3,012,068 shares of Vigil Neuroscience common stock, representing 6.45% of the class as of the reporting event date 06/30/2025. The filing indicates the Reporting Persons have shared voting and shared dispositive power over these shares and no sole voting or dispositive power. The statement identifies Glazer Capital as an investment manager and Mr. Glazer as its managing member and includes the issuer's principal office in Watertown, MA. The Reporting Persons certify the shares were not acquired to change or influence control of the issuer. The filing is signed 08/14/2025.

Positive

• Public disclosure of a material stake: 3,012,068 shares (6.45% of class) are reported, meeting SEC reporting thresholds
• Transparency on control: Filing states shared voting and dispositive power and includes a certification that the holdings are not intended to influence control

Negative

• No sole voting or dispositive power: Reporting Persons report 0 shares with sole voting or dispositive authority, limiting direct control influence

Insights

Securities Analyst

TL;DR: Glazer Capital and Paul Glazer disclose a 6.45% beneficial stake with shared control, filed under Schedule 13G/A.

The filing documents a material disclosure because the reported position exceeds 5% of the outstanding class, requiring public reporting. The record shows 3,012,068 shares with shared voting and dispositive power, and explicitly notes no sole voting or dispositive power. The statement also contains a certification that the holdings were not acquired to influence control, which frames the position as passive under the filing rules.

Corporate Governance Expert

TL;DR: A >5% passive disclosure with shared authority; notable for governance monitoring but not an asserted control change.

The Schedule 13G/A identifies both an entity (Glazer Capital, an investment manager) and an individual (Paul J. Glazer) as Reporting Persons and confirms shared authority over the reported shares. For governance purposes, investors should note the 6.45% stake is large enough to merit attention but the filing includes a certification that it was not intended to change control, indicating a passive reporting posture rather than an activist intent.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

Vigil Neuroscience, Inc.

(Name of Issuer)

Common Stock, $0.0001 par value per share

(Title of Class of Securities)

92673K108

(CUSIP Number)

06/30/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 92673K108

1

Names of Reporting Persons

Glazer Capital, LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 3,012,068.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 3,012,068.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,012,068.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.45 %

12

Type of Reporting Person (See Instructions)

IA, OO

SCHEDULE 13G

CUSIP No. 92673K108

1

Names of Reporting Persons

Paul J. Glazer

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 3,012,068.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 3,012,068.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,012,068.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.45 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Vigil Neuroscience, Inc.
(b)	Address of issuer's principal executive offices: 100 Forge Road, Suite 700, Watertown, MA, 02472
Item 2.
(a)	Name of person filing: This statement is filed by: (i) Glazer Capital, LLC, a Delaware limited liability company ("Glazer Capital"), with respect to the shares of Common Stock (as defined in Item 2(d)) held by certain funds and managed accounts to which Glazer Capital serves as investment manager (collectively, the "Glazer Funds"); and (ii) Mr. Paul J. Glazer ("Mr. Glazer"), who serves as the Managing Member of Glazer Capital, with respect to the shares of Common Stock held by the Glazer Funds. The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons." The filing of this statement should not be construed as an admission that any of the Reporting Persons is, for the purposes of Section 13 of the Act, the beneficial owner of the shares of Common Stock (as defined in Item 2(d)) reported herein.
(b)	Address or principal business office or, if none, residence: The address of the business office of each of the Reporting Persons is 250 West 55th Street, Suite 30A, New York, New York 10019.
(c)	Citizenship: Glazer Capital is a Delaware limited liability company. Mr. Glazer is a United States citizen.
(d)	Title of class of securities: Common Stock, $0.0001 par value per share
(e)	CUSIP No.: 92673K108
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 3012068
(b)	Percent of class: 6.45%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0
	(ii) Shared power to vote or to direct the vote: 3012068
	(iii) Sole power to dispose or to direct the disposition of: 0
	(iv) Shared power to dispose or to direct the disposition of: 3012068
Item 5.	Ownership of 5 Percent or Less of a Class.
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. See Item 2.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Glazer Capital, LLC

Signature:	Paul J. Glazer
Name/Title:	Paul J. Glazer, Managing Member
Date:	08/14/2025

Paul J. Glazer

Signature:	Paul J. Glazer
Name/Title:	Paul J. Glazer
Date:	08/14/2025

FAQ

What stake did Glazer Capital and Paul J. Glazer report in VIGL?

They reported beneficial ownership of 3,012,068 shares, representing 6.45% of Vigil Neuroscience common stock.

When is the reporting event date for the Schedule 13G/A for VIGL?

The date of the event requiring this filing is 06/30/2025.

Does Glazer Capital or Paul Glazer have sole voting or dispositive power over the reported VIGL shares?

No. The filing shows 0 shares with sole voting power and 0 shares with sole dispositive power; both powers are reported as shared for 3,012,068 shares.

Did the Reporting Persons state an intent to influence control of Vigil Neuroscience (VIGL)?

No. The certification states the securities were not acquired and are not held to change or influence the control of the issuer.

Who filed the Schedule 13G/A and where is the issuer located?

The filing was made by Glazer Capital, LLC and Paul J. Glazer. The issuer's principal executive offices are listed at 100 Forge Road, Suite 700, Watertown, MA 02472.

When was this Schedule 13G/A signed?

The signatures on the filing are dated 08/14/2025.